viewMedical Australia

Medical Australia to acquire animal stem cell technology company MediVet


Medical Australia (ASX: MLA) has now signed an agreement to acquire Medivet Pty Ltd, which is a private Australian company with proprietary ownership technology for regenerative stem cell technology for domestic animals and the equine industry.

Consideration for the deal will by around 36.6 million shares at $0.30 for total consideration of $11 million.

MLA announced in June this year that it intended to acquire MediVet for $10 million in a 50/50 cash and scrip transaction.

The latest agreement has been executed in order to provide a quicker close so immediate business opportunities can be pursued. The acquisition is subject to shareholder approval.

The acquisition by MLA is company transforming, and it creates a unique and profitable human and animal healthcare company with a global footprint.

MediVet back story

Founded in 2008, MediVet is a leader in the animal healthcare market and has developed a range of animal healthcare products which are highly regarded in a number of global markets.

The company is best known for developing the world-first in house regenerative animal stem-cell technology which has been commercialised for the veterinary and equine markets throughout the world.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Quick facts: Medical Australia

Price: - -

Market: ASX
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Pan Asia Metals says drilling at Khao Soon Tungsten project is going well

Pan Asia Metals Limited's (ASX:PAM) Paul Lock caught up with Proactive's Andrew Scott soon after announcing they've been formally awarded Special Prospecting Licence TSPL 2/2563 for the Khao Soon Tungsten Project in Thailand. It's a wolframite style tungsten project about 600 kilometres south of...

9 hours, 20 minutes ago

2 min read